Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.3731
+0.0076 (2.08%)
At close: Aug 7, 2025, 4:00 PM
0.3728
-0.0003 (-0.08%)
Pre-market: Aug 8, 2025, 5:37 AM EDT

Company Description

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).

Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.

The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017.

Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Veru Inc.
Veru Inc. logo
CountryUnited States
Founded1971
IPO DateJul 19, 1990
IndustryBiotechnology
SectorHealthcare
Employees210
CEOMitchell Steiner

Contact Details

Address:
2916 North Miami Avenue, Suite 1000
Miami, Florida 33127
United States
Phone305 509 6897
Websiteverupharma.com

Stock Details

Ticker SymbolVERU
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code0000863894
CUSIP Number92536C103
ISIN NumberUS92536C1036
Employer ID39-1144397
SIC Code2834

Key Executives

NamePosition
Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President and Chief Executive Officer
Dr. Harry D. Fisch F.A.C.S., M.D.Vice Chairman and Chief Corporate Officer
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer
Michele Greco CPAChief Financial Officer and Chief Administrative Officer
Samuel FischExecutive Director of Investor Relations and Corporate Communications
Michael J. Purvis J.D.Executive Vice President, General Counsel and Corporate Strategy and Secretary
Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate Development
Martin TaylerExecutive Vice President of FC2 Global Operations
Philip R. Greenberg J.D.Executive Vice President and Deputy General Counsel
Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical Operations

Latest SEC Filings

DateTypeTitle
Jul 25, 20258-KCurrent Report
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 15, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 10, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 10, 2025DEF 14AOther definitive proxy statements
May 9, 2025PRE 14AOther preliminary proxy statements
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Mar 14, 20258-KCurrent Report
Feb 28, 20258-KCurrent Report